Lexicon Pharmaceuticals (NASDAQ:LXRX) Issues Quarterly Earnings Results, Beats Expectations By $0.80 EPS

Share on StockTwits

Lexicon Pharmaceuticals (NASDAQ:LXRX) announced its earnings results on Thursday. The biopharmaceutical company reported $2.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.31 by $0.80, Fidelity Earnings reports. The business had revenue of $294.45 million for the quarter, compared to the consensus estimate of $12.00 million. The business’s quarterly revenue was up 4124.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.26) earnings per share.

Shares of LXRX traded down $0.36 during mid-day trading on Friday, reaching $3.52. The stock had a trading volume of 1,316,800 shares, compared to its average volume of 1,292,482. The firm has a market cap of $419.77 million, a price-to-earnings ratio of -3.09 and a beta of 0.95. The business has a fifty day moving average of $3.52 and a 200 day moving average of $4.21. Lexicon Pharmaceuticals has a 12 month low of $1.13 and a 12 month high of $9.15.

Several analysts recently issued reports on the stock. Stifel Nicolaus lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating and cut their target price for the company from $10.00 to $4.00 in a research report on Monday, July 29th. Citigroup lowered shares of Lexicon Pharmaceuticals from a “buy” rating to a “neutral” rating and boosted their target price for the company from $3.00 to $4.00 in a research report on Friday. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a research report on Saturday. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 5th. Finally, Wedbush restated a “buy” rating and set a $17.00 target price on shares of Lexicon Pharmaceuticals in a research report on Friday, October 4th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $6.45.

In other news, Director Christopher J. Sobecki bought 25,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Monday, September 16th. The shares were acquired at an average price of $2.55 per share, with a total value of $63,750.00. Following the completion of the purchase, the director now owns 112,493 shares in the company, valued at approximately $286,857.15. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Lonnel Coats bought 37,000 shares of Lexicon Pharmaceuticals stock in a transaction dated Friday, August 16th. The stock was purchased at an average cost of $1.35 per share, for a total transaction of $49,950.00. Following the purchase, the chief executive officer now owns 87,695 shares of the company’s stock, valued at approximately $118,388.25. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 255,749 shares of company stock worth $578,510. 6.40% of the stock is owned by insiders.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Featured Story: How to invest using market indexes

Earnings History for Lexicon Pharmaceuticals (NASDAQ:LXRX)

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Hudson Pacific Properties  Research Coverage Started at Goldman Sachs Group
Hudson Pacific Properties Research Coverage Started at Goldman Sachs Group
Hi-Crush  Rating Lowered to Underperform at AltaCorp Capital
Hi-Crush Rating Lowered to Underperform at AltaCorp Capital
Dicerna Pharmaceuticals  Upgraded to Strong-Buy at BidaskClub
Dicerna Pharmaceuticals Upgraded to Strong-Buy at BidaskClub
Icahn Enterprises  Lowered to “Strong Sell” at BidaskClub
Icahn Enterprises Lowered to “Strong Sell” at BidaskClub
Lexicon Pharmaceuticals  Issues Quarterly  Earnings Results, Beats Expectations By $0.80 EPS
Lexicon Pharmaceuticals Issues Quarterly Earnings Results, Beats Expectations By $0.80 EPS
Zacks: Analysts Expect Four Corners Property Trust Inc  Will Post Quarterly Sales of $41.39 Million
Zacks: Analysts Expect Four Corners Property Trust Inc Will Post Quarterly Sales of $41.39 Million


© 2006-2019 Ticker Report